Invivyd, Inc. cotiza a 0.65 USD y tiene una capitalización bursátil de $190M. En los últimos 12 meses ha facturado $58M con un margen de flujo de caja libre del -109.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-e…
| Periodo | 2026-08 | 2026-05 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | — | $-0.13 | $-0.06 | $-0.12 |
| Estimado | $-0.14 | $-0.08 | $-0.09 | $0.01 |
| Sorpresa | — | -62.5% | +33.3% | -1300.0% |
| Métrica | IVVD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -104.0% | -38.6% | -65.4% |
| Net Margin | -98.3% | -33.6% | -64.7% |
| FCF Margin | -109.1% | -13.9% | -95.2% |
| ROE | -21.7% | -40.4% | +18.7% |
| ROA | -19.0% | -32.0% | +13.0% |
| Current Ratio | 7.24 | 2.84 | +4.40 |
| Debt / Equity | — | 0.28 | — |